New pill targets Hard-to-Treat cancers in early human trial
NCT ID NCT06799065
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 participants will take part in this first-in-human trial.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Florida Cancer Specialists
RECRUITINGSarasota, Florida, 34232, United States
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
NEXT Oncology
RECRUITINGSan Antonio, Texas, 78229, United States
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
-
SCRI Oncology Partners
RECRUITINGNashville, Tennessee, 37203, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can a new PET tracer light up hidden cancers?